| Primary |
| Product Used For Unknown Indication |
20.1% |
| Chronic Lymphocytic Leukaemia |
16.5% |
| Peripheral T-cell Lymphoma Unspecified |
7.6% |
| Infection Prophylaxis |
6.8% |
| Premedication |
6.3% |
| Prophylaxis |
5.7% |
| Multiple Sclerosis |
5.7% |
| T-cell Lymphoma |
3.9% |
| Stem Cell Transplant |
3.9% |
| Prophylaxis Against Graft Versus Host Disease |
3.8% |
| Bone Marrow Conditioning Regimen |
3.5% |
| Acute Lymphocytic Leukaemia |
3.1% |
| Antiviral Prophylaxis |
2.0% |
| Antifungal Prophylaxis |
1.9% |
| Immunosuppressant Drug Therapy |
1.9% |
| Renal Transplant |
1.7% |
| Immunosuppression |
1.5% |
| Neutropenia |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| T-cell Prolymphocytic Leukaemia |
1.1% |
|
| Pyrexia |
11.5% |
| Death |
10.1% |
| Pneumonia |
7.5% |
| Vomiting |
7.3% |
| White Blood Cell Count Decreased |
7.1% |
| Thrombocytopenia |
6.4% |
| Septic Shock |
4.9% |
| Sepsis |
4.7% |
| Transplant Rejection |
4.7% |
| Pancytopenia |
3.8% |
| Urticaria |
3.7% |
| Cytomegalovirus Infection |
3.5% |
| Renal Failure |
3.5% |
| Neutropenia |
3.3% |
| Febrile Neutropenia |
3.1% |
| Respiratory Failure |
3.1% |
| Idiopathic Thrombocytopenic Purpura |
3.0% |
| Transplant Failure |
3.0% |
| Wheezing |
3.0% |
| Disease Progression |
2.8% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
16.1% |
| Product Used For Unknown Indication |
12.0% |
| Peripheral T-cell Lymphoma Unspecified |
11.1% |
| Infection Prophylaxis |
8.2% |
| Premedication |
8.0% |
| Stem Cell Transplant |
6.4% |
| Bone Marrow Conditioning Regimen |
6.2% |
| Prophylaxis |
5.7% |
| Prophylaxis Against Graft Versus Host Disease |
4.7% |
| Drug Use For Unknown Indication |
3.5% |
| Antiviral Prophylaxis |
2.9% |
| Multiple Sclerosis |
2.6% |
| Antifungal Prophylaxis |
2.5% |
| T-cell Lymphoma |
2.1% |
| T-cell Prolymphocytic Leukaemia |
1.7% |
| Acute Lymphocytic Leukaemia |
1.5% |
| Immunosuppression |
1.4% |
| Combined Immunodeficiency |
1.3% |
| Anaemia |
1.1% |
| Antibiotic Prophylaxis |
0.9% |
|
| Pyrexia |
13.2% |
| Vomiting |
12.1% |
| Respiratory Failure |
6.6% |
| White Blood Cell Count Decreased |
5.7% |
| Pneumonia |
5.2% |
| Epstein-barr Virus Infection |
4.8% |
| Septic Shock |
4.5% |
| Renal Failure |
4.4% |
| Leukopenia |
4.2% |
| Pericarditis |
4.1% |
| Thrombocytopenia |
4.1% |
| Pancytopenia |
3.8% |
| Perineal Ulceration |
3.8% |
| Transplant Rejection |
3.6% |
| Death |
3.5% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
3.5% |
| Urinary Tract Infection |
3.3% |
| Venous Thrombosis Limb |
3.3% |
| Infusion Related Reaction |
3.2% |
| Infection |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.1% |
| Chronic Lymphocytic Leukaemia |
14.3% |
| Stem Cell Transplant |
8.5% |
| Bone Marrow Conditioning Regimen |
8.3% |
| Drug Use For Unknown Indication |
6.7% |
| Immunosuppressant Drug Therapy |
5.0% |
| Idiopathic Thrombocytopenic Purpura |
3.8% |
| Prophylaxis Against Graft Versus Host Disease |
3.5% |
| Acute Myeloid Leukaemia |
2.7% |
| Constipation |
2.6% |
| Malaise |
2.6% |
| Blood Pressure |
2.1% |
| Prophylaxis |
2.1% |
| Chronic Lymphocytic Leukaemia Refractory |
1.9% |
| Cytomegalovirus Infection |
1.9% |
| Hepatic Candidiasis |
1.9% |
| Graft Versus Host Disease |
1.8% |
| Allogenic Bone Marrow Transplantation Therapy |
1.4% |
| Combined Immunodeficiency |
1.4% |
| Antiviral Prophylaxis |
1.3% |
|
| Progressive Multifocal Leukoencephalopathy |
16.3% |
| Perineal Ulceration |
8.1% |
| Sepsis |
8.1% |
| Graft Versus Host Disease |
5.8% |
| Thrombotic Microangiopathy |
5.8% |
| Cytokine Release Syndrome |
4.7% |
| Syncope |
4.7% |
| Transplant Failure |
4.7% |
| Acute Graft Versus Host Disease In Skin |
3.5% |
| Cytomegalovirus Chorioretinitis |
3.5% |
| Cytomegalovirus Infection |
3.5% |
| Infection |
3.5% |
| Malignant Neoplasm Progression |
3.5% |
| Muscular Weakness |
3.5% |
| Nephrotic Syndrome |
3.5% |
| Off Label Use |
3.5% |
| Overdose |
3.5% |
| Pyrexia |
3.5% |
| Rash |
3.5% |
| Venous Insufficiency |
3.5% |
|
